Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan

Journal of Clinical Medicine

Masayuki Honda¹  Reina Sasaki¹  Mariko Kumagawa¹  Tatsuo Kanda¹  Taku Mizutani¹  Ryota Masuzaki¹  Kazushige Nirei¹  Hiroaki Yamagami¹  Mitsuhiko Moriyama¹  Shini Kanezawa¹  Naoki Matsumoto¹  Tomotaka Ishii¹  Yoichiro Yamana¹ 

[1] Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan;

关键词: chronic kidney disease;    DAA failure;    hemodialysis;    HCV;    NS5A P32 deletion mutant;   

DOI  :  10.3390/jcm10235529

来源: DOAJ

【 摘 要 】

Hepatis virus C (HCV) infection causes liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The objective of our study was to examine the effects of the HCV nonstructural protein (NS) 3/4A inhibitor glecaprevir/NS5A inhibitor pibrentasvir on real-world HCV patients in the northern part of Tokyo, Japan. Although 106 patients were consecutively included, a total of 102 HCV-infected patients with chronic hepatitis or compensated cirrhosis, who received 8- or 12-week combination treatment with glecaprevir/pibrentasvir and were followed up to week 12 after the end of treatment were analyzed retrospectively. Only three patients discontinued treatment due to adverse events; however, they achieved a sustained virologic response at 12 weeks (SVR12). Finally, SVR rates were 99.0% (101/102). Only one patient without liver cirrhosis was a treatment relapser who received hepatic resection for HCC approximately two years after commencement of the 8-week combination treatment with glecaprevir/pibrentasvir. After the exclusion of patients with HCV genotype 1b and P32 deletion in the HCV NS5A region, a 12-week combination of glecaprevir/pibrentasvir led to SVR12 in all nine direct-acting antiviral-experienced patients. Glecaprevir/pibrentasvir had a high efficacy and an acceptable safety profile for real-world HCV patients in a single hospital in Japan.

【 授权许可】

Unknown